Flare Therapeutics Funding & Investors
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
flaretx.comTotal Amount Raised: $205,000,000
Flare Therapeutics Funding Rounds
Series B
$123,000,000
Series B Investors
EventideMemorial Sloan Kettering Cancer CenterEli LillyPfizer Venture InvestmentsNextech InvestGordonMD Global InvestmentsPavilion CapitalNovartisAgent CapitalInvus GroupThird Rock VenturesShangbay CapitalCasdin CapitalBoxer CapitalSeries A
$82,000,000
Series A Investors
EventideInvus GroupThird Rock VenturesNextech InvestCasdin CapitalBoxer Capital